The nephrotic syndrome: From the simple to the complex

Seminars in Nephrology

Volumn 18, Issue 3, 1998, Pages 304-316

  Eddy, Allison A ^a,b   William Schnaper, H ^c,d,e  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Pediatrics W 140   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PROSTAGLANDIN INHIBITOR;

CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CONGENITAL NEPHROTIC SYNDROME; DIFFERENTIAL DIAGNOSIS; FOCAL GLOMERULONEPHRITIS; GENETIC LINKAGE; GLOMERULOSCLEROSIS; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; VITAMIN D METABOLISM;

CHILD; HUMANS; KIDNEY; NEPHROTIC SYNDROME;

EID: 0031976431     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. North American Pediatric Renal Transplant Cooperative Study. 1997 Annual Report, 1997
2. Kirn Y, Michael AF, Tarshish P: Infection and nephritis, in Edelmann CM, Bernstein J, Meadow SR, Spitzer A, Travis LB (eds): Pediatric Kidney Disease. Boston, MA, Little Brown, 1992, pp 1569-1584
3. Gubler MC, Antignac C, Knebelman B: Inherited glomerular disease, in Holliday MA, Barrait TM, Avner ED, Kogan BA (eds): Pediatric Nephrology. Baltimore, MD, Williams and Wilkins, 1994, pp 515-536
4. Glassock RJ, Cohen AH, Adler SG: Primary glomerular diseases, in Brenner BM (ed): The Kidney. Philadelphia, PA, Saunders, 1996, pp 1392-1497
5. Brenner BM, Hosteller TH, Humes HD: Molecular basis of proteinuria of glomerular origin. N Engl J Med 298: 826-833, 1978
6. Robson AM, Cole BR: Pathologic and functional correlations in the glomerulopathies, in Cummings NB, Michael AF, Wilson CB (eds): Immune Mechanisms in Renal Disease. New York, NY, Plenum, 1982, p 109
7. Carric BJ, Salyer WR, Myers BD: Minimal change nephropathy: An electrochemical disorder of the glomerular membranes. Am J Med 70:262-268, 1981
8. Schnaper HW, Robson AM: Nephrotic syndrome: Minimal change disease, focal glomerulosclerosis and related disorders, in Schrier RW, Gottschalk CM (eds): Diseases of the Kidney, 6th ed. Boston, MA, Little, Brown and Co., 1996, pp 1725-1780
9. Vernier RL, Klein DJ, Sisson SP, et al: Heparan sulfaterich anionic sites in the human glomerular basement membrane. Decreased concentrations in congenital nephrotic syndrome. N Engl J Med 309:1001-1009, 1983
10. Blau EB, Haas JE: Glomerular sialic acid and proteinuria in human renal disease. Lab Invest 38:447-481, 1973
11. Ljunberg P, Rapola J, Holmberg C, et al: Glomerular anionic charge in congenital nephrotic syndrome of the Finnish type. Histochem J 27:536-546, 1995
12. Van den Heuvel LP, Van den Bom J, Jalanko H, et al: The glycosaminoglycan content of renal basement membranes in the congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol 6:10-15, 1992
13. Vehaskari VM, Root ER, Germuth FG, et al: Glomerular charge and urinary protein excretion: Effects of systemic and intrarenal polycation infusion in the rat. Kidney Int 22: 127-135, 1982
14. Shemesh O, Deen WM, Brenner BM, et al: Effect of colloid volume expansion on glomerular barrier size selectivity in humans. Kidney Int 29:916-923, 1986
15. Tomlinson PA, Dalton RN, Hartley B, et al: Low molecular weight protein excretion in glomerular disease: A comparative analysis. Pediatr Nephrol 11:285-290, 1997
16. Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T-cells function. Lancet ii:556-560, 1976
17. Holdsworth SR, Neale TJ, Wilson CB: Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. J Clin Invest 68:686-698, 1981
18. Garin EH, West L, Zheng W: Effect of interleukin-8 on glomerular sulfated compounds and albuminuria. Pediatr Nephrol 11:274-279, 1997
19. Tomizawa S, Maruyama K, Nagasawa N, et al: Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome. Nephron 41:157-160, 1985
20. Tanaka R, Yoshikawa N, Nakamura H, et al: Infusion of peripheral blood mononuclear cell products from nephrotic children increases albuminuria in rats. Nephron 60:35-41, 1992
21. Bakker WW, Bailer JFW, vanLuijk WHJ, et al: A kallikrein-like molecule and vasoactivity in minimal change disease. Increased turnover in relapse vs. remission. Contrib Nephrol 67:31-36, 1988
22. Keller H, Morell A, Noseda G, et al: Analbuminamic Pathophysiologische Untersuchungen an einem Fall. Schweiz Med Wochenschr 102:33-41, 1972
23. Rosenman RH, Byres SO, Friedman M: Plasma lipid interrelationships in experimental nephrosis. J Clin Invest 36: 1558, 1957
24. Kaysen GA: Hyperlipidemia in the nephrotic syndrome. Am J Kidney Dis 12:548-551, 1988
25. Dixit VM, Hettiaratchi ES: The mechanism of hyperlipidemia in the nephrotic syndrome. Med Hypotheses 5: 1327-1331, 1979
26. Sagripanti A, Barsotti G: Hypercoagulability, intra-glomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron 70:271-281, 1995
27. Hoyer PF, Gonda S, Barthels M, et al: Thromboembolic complications in children with nephrotic syndrome. Acta Paediatr Scand 75:804-810, 1986
28. Andrassy K, Ritz E, Bommer J: Hypercoagulability in the nephrotic syndrome. Klin Wochenchr 58:1029-1036, 1980
29. Vigano-D'Angelo S, D'Angelo A, Kaufman CEJ, et al: Protein S deficiency occurs in the nephrotic syndrome. Ann Int Med 107:42-47, 1987
30. Garbrecht F, Gardner S, Johnson V, et al: Deep venous thrombosis in a child with nephrotic syndrome associated with a circulating anticoagulant and acquired protein S deficiency. Am J Pediatr Hematol Oncol 13:330-333, 1991
31. Goldstein DA, Haldimann B, Sherman D, et al: Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 52:116-121, 1981
32. Freundlich M, Jofe M, Saluski I, et al: Bone histopathology in children with nephrotic syndrome and normal glomerular filtration rate. J Am Soc Nephrol 5:849, 1994 (abstr)
33. Lettgen B, Jeken C, Reiners C: Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol 8:667-670, 1994
34. International Study of Kidney Disease in Children: The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561, 1981
35. Border WA, Noble NA: TGF-β in kidney fibrosis: A target for gene therapy. Kidney Int 51:1388-1396, 1997
36. Kanai H, Mitsuhashi H, Ono K, et al: Increased excretion of urinary transforming growth factor beta in patients with focal glomerulosclerosis. Nephron 66:391-395, 1994
37. Wang DH, Du Y, Zhao H, et al: Regulation of angiotensin type 1 receptor and its gene expression: role in renal growth. J Am Soc Nephrol 8:193-198, 1997
38. Kagami S, Border W, Ruoslahti E, et al: Coordinated expression of β1 integrins and transforming growth factor-β-induced matrix proteins in glomerulonephritis. Lab Invest 69:68-76, 1993
39. 1-independent mechanism. Kidney Int 52:637-647, 1997
40. Floege J, Eng E, Toung BA, et al: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 92:2952-2962, 1993
41. Stein-Oakley AN, Maguire JA, Dowling J, et al: Altered expression of fibrogenic growth factors in IgA nephropathy and focal segmental glomerulosclerosis. Kidney Int 51: 195-204, 1997
42. Hocher B, Thone-Reineke C, Rohmeiss P, et al: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380-1389, 1997
43. Trachtman H, Futterweit S, Singhai P: Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Comm 207:120-125, 1995
44. Magil A: Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant. J Am Soc Nephrol 7:2340-2347, 1996
45. Turck J, Pollock AS, Lovett DH: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 51:1397-1400, 1997
46. Fogo A, Ichikawa I: Evidence for the central role of glomerular growth promoters in the development of sclerosis. Semin Nephrol 9:329-342, 1989
47. Foidart JM, Foidart JB, Mahieu PR: Synthesis of collagen by glomerular cells in culture. Renal Physiol Basel 3: 183-192, 1980
48. Johnson RJ, Iida H, Alpers CE, et al: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis, α-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 87:847-858, 1991
49. Hiroi J, Kimura K, Aikawa M, et al: Expression of a nonmuscle myosin heavy chain in glomerualr cells differentiates various types of glomerular disease in rats. Kidney Int 49:1231-1241, 1996
50. Schnaper HW, Kleinman HK: Regulation of cell function by extracellular matrix. Pediatr Nephrol 7:96-104, 1992
51. Faubert PF, Porush JG: Familial focal segmental glomerulosclerosis: Nine cases in four families and review of the literature. Am J Kidney Dis 30:265-270, 1997
52. Freedman BI, Wilson CH, Spray BJ, et al: Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis 29:729-732, 1997
53. Pettitt DJ, Saad MF, Bennett PH, et al: Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33:438-443, 1990
54. Cambien F, Poirier O, Lecerf L, et al: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641-644, 1992
55. Parving H-H, Tarnow L, Rossing P: Genetics of diabetic nephropathy. J Am Soc Nephrol 7:2509-2517, 1996
56. Pontrenoli R, Sofia A, Tirotta A, et al: The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 7:2550-2558, 1996
57. Risdon RA, Sloper JC, de Vardener HE: Relationship between renal function and histologic changes found in renalbiopsy specimens from patients with persistent glomerulonephritis. Lancet 2:363-366, 1968
58. Schainuck LI, Stricker GE, Cutler RE, et al: Structural-functional correlations in renal disease. Part II. The correlations. Hum Pathol 1:631-641, 1970
59. Perna A, Remuzzi G: Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. Am J Kidney Dis 27:34-41, 1996
60. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 123:754-762, 1995
61. Eddy AA, Michael AF: Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int 33: 14-23, 1988
62. Eddy AA: Protein restriction reduces transforming growth factor-β and interstitial fibrosis in nephrotic syndrome. Am J Physiol 266:F884-F893, 1994
63. Kamper A-L, Holstein-Rathlou N-H, Leyssac PP, et al: The influence of angiotensin-converting enzyme on renal tubular function in progressive chronic nephropathy. Am. J Kidney Dis 28:822-831, 1996
64. Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47:1546-1557, 1995
65. Mon H, Yamashita H, Nakanishi C, et al: Proteinuria induced by transplantable rat pituitary tumor MtT SA5. Model for homologous protein-overload proteinuria. Lab Invest 54:636-644, 1986
66. Bertani T, Cutillo F, Zoja C, et al: Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 30:488-496, 1986
67. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
68. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
69. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273-1287, 1994
70. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 49:578-597, 1996
71. Maack T, Park CH, Camargo MJF: Renal filtration, transport, and metabolism of proteins, in Brenner BM, Rector FC (eds): The Kidney: Physiology and Pathophysiology. New York, NY, Raven Press, 1985, pp 1773-1803
72. Nankivell BJ, Boadle RA, Harris D: Iron accumulation in human chronic renal disease. Am J Kidney Dis 20:580-584, 1992
73. Alfrey AC: Role of iron and oxygen radicals in the progression of chronic renal failure. Am J Kidney Dis 23: 183-187, 1994
74. Kees-Folts D, Sadow JL, Schreiner GF: Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 45:1697-1709, 1994
75. Hirschberg R: Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions. J Clin Invest 98:116-124, 1996
76. Kallen RJ, Brynes RK, Aronson AI, et al: Premature coronary atherosclerosis in a 5-year-old with corticosteroid-refractory nephrotic syndrome. Am J Dis Child 131:976, 1977
77. Portman R, Hawkins E, Verani R: Premature atherosclerosis in pediatric renal patients: Report of the Southwest Pediatric Nephrology Study Group. Pediatr Res 29:2075A, 1991
78. Ordoñez JD, Hiatt RA, Killebrew EJ, et al: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1995
79. Massy ZA, Ma JZ, Louis TA, et al: Lipid-lowering therapy in patients with renal disease. Kidney Int 48:188-198, 1995
80. Schlondorff D: Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 22:72-82, 1993
81. Moorehead JF, Chan MK, El-Nahas M, et al: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2:1309-1311, 1982
82. Magil AB: Tubulointerstitial lesions in young Zucker rats. Am J Kidney Dis 25:478-485, 1995
83. Kasiske BL, O'Donnell MP, Cleary MP, et al: Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int 35:40-47, 1989
84. Kasiske BL, O'Donnell MP, Schmilz PG, et al: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 37:880-891, 1990
85. Peric-Golia L, Peric-Gloia M: Aortic and renal lesions in hypercholesterolemic adult, male virgin Sprague-Dawley rats. Atherosclerosis 46:57-65, 1983
86. Wellman KF, Volk BW: Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long-term studies. Lab Invest 24:144-155, 1971
87. Trachtman H, Schwob N, Maesaka J, et al: Dietary vitamin E supplementation ameliorates renal injury in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 5:1811-1819, 1995
88. Lee HS, Jeong JY, Kim BC, et al: Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int 51:1151-1159,1997
89. Quinn MT, Parthasarathy S, Fong LGS D: Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 84:2995-2998, 1987
90. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, et al: Ex-pression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252-5256, 1991
91. Khan BV, Parthasarapthy SS, Alexander RW, et al: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 95:1262-1270, 1995
92. Lehr H-A, Kröber M, Hübner C, et al: Stimulation of leukocyte/endothelium interaction by oxidized low-density lipoprotein in hairless mice. Involvement of CD11b/CD18 adhesion receptor complex. Lab Invest 68:388-395, 1993
93. Eitzman DT, McCoy RD, Zheng X, et al: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97:232-237, 1996
94. Tune BM, Lieberman E, Mendoza SA: Steroid-resistant focal segmental glomerulosclerosis: A treatable disease. Pediatr Nephrol 10:772-778, 1996
95. Gansevoort RT, de Zeeuw D, de Jong PE: Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 22:202-206, 1993
96. Yoshida H, Matarai T, Kawamura T, et al: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96:2162-2169, 1995